FGFR1 rearrangement signaling
Current understanding
To be populated as evidence accumulates.
Evidence log
- April 28, — FDA Approves Pemazyre (Pemigatinib) for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement: FDA approval of pemigatinib for relapsed/refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement based on FIGHT-203 (78% complete response in chronic phase) provides the first clinical validation that constitutively active FGFR1 fusion kinase signaling is a pharmacologically targetable driver in this MPN subtype. (novelty: 4)
Open questions
Related
Contributing findings
FDA Approves Pemazyre (Pemigatinib) for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
April 28, 2026
novelty 4
per-area 4
introduces